BioNTech Stock Target Price and Analyst Consensus
| BNTX Stock | USD 86.81 0.64 0.74% |
The current analyst and expert consensus on BioNTech is Buy with 8 hold recommendations. The current projected BioNTech target price consensus is 151.10 with 19 analyst opinions. One of the most common ways BioNTech SE analysts use to provide buy-or-sell recommendation to the public are conference calls analysis and financial statements evaluations. Some experts can also talk to BioNTech vendors, executives, and/or customers. BioNTech recommendation module provides expert sentiment on the projected BioNTech SE target price to derive its highest and lowest estimates based on target price standard deviation of 0.0. Check out Macroaxis Advice on BioNTech to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon.
Lowest Forecast 137.5 | Highest Forecast 167.72 | Target Price 151.1 |
BioNTech |
It's important to approach BioNTech's target price projections with caution. While they can be useful as part of a broader investment strategy, they are inherently speculative and subject to various kinds of risk, including market volatility and unforeseen external factors. Always consider multiple aspects and do your own research when making investment decisions.
Analysts determine stock price targets through various methods, including financial modeling, peer comparison, and company analysis. The stock price target is the analyst's best estimate of the future price of a stock and is used by investors to make investment decisions. However, it is important to note that stock price targets are not guaranteed, and the actual price of a stock can differ significantly from the target due to various factors such as market conditions, economic events, and company developments.
Steps to utilize BioNTech price targets
BioNTech's stock target price is an estimate of its future price, usually made by analysts. Using BioNTech's target price to determine if it is a suitable investment can be done through the following steps:- Look at BioNTech's target prices provided by various analysts and compare them. This can help you gain a more balanced view of the Stock's potential.
- Look at the analyst's track record to determine if they have a history of accurately predicting stock prices.
- Look at the Company's financials, including revenue, earnings, and debt, to determine if it is in good financial health.
- Consider market conditions. For example, take into account the state of the economy, competition, and regulatory environment, to determine if BioNTech's stock is likely to perform well.
- Diversify your portfolio and do not rely solely on stock target prices to make investment decisions. Invest in a mix of stocks, bonds, and other assets to manage risk.
Additional BioNTech Value Projection Modules
Most investment researchers agree that the mispricing and readjustment of any Stock value happens often and is sometimes even predictable, but there is no strong theory explaining why it happens. The current price of BioNTech is a key component of BioNTech valuation and have some predictive power on the future returns of a BioNTech.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of BioNTech's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Trending Themes
If you are a self-driven investor, you will appreciate our idea-generating investing themes. Our themes help you align your investments inspirations with your core values and are essential building blocks of your portfolios. A typical investing theme is an unweighted collection of up to 20 funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of equities with common characteristics such as industry and growth potential, volatility, or market segment. | FinTech Invested over 70 shares | |
 | Manufacturing Invested over 40 shares | |
 | Investor Favorites Invested over 200 shares | |
 | Banking Invested over 30 shares | |
 | Driverless Cars Invested few shares | |
 | Automobiles and Trucks Invested over 200 shares | |
 | Macroaxis Index Invested few shares | |
 | Momentum Invested over 200 shares | |
 | Chemicals Invested over 40 shares | |
Check out Macroaxis Advice on BioNTech to cross-verify analyst projections. Unlike analyst recommendations, Macroaxis provides advice only from the perspective of investor risk tolerance and investment horizon. You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Complementary Tools for BioNTech Stock analysis
When running BioNTech's price analysis, check to measure BioNTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioNTech is operating at the current time. Most of BioNTech's value examination focuses on studying past and present price action to predict the probability of BioNTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioNTech's price. Additionally, you may evaluate how the addition of BioNTech to your portfolios can decrease your overall portfolio volatility.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |
The data published in BioNTech's official financial statements usually reflect BioNTech's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of BioNTech SE. For example, before you start analyzing numbers published by BioNTech accountants, it's critical to develop an understanding of what BioNTech's liquidity, profitability, and earnings quality are in the context of the Biotechnology space in which it operates.
Please note, the presentation of BioNTech's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioNTech's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in BioNTech's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of BioNTech SE. Please utilize our Beneish M Score to check the likelihood of BioNTech's management manipulating its earnings.